Background: Optimal management and treatment of type-1 gastric carcinoids is under debate. Aims: This prospective study evaluates the outcome of patients with recurrent type-1 gastric carcinoids treated with somatostatin analogues. Methods: From 2000 to 2013, among a population of 107 chronic atrophic gastritis patients, 25 (20% males, median age 62 years) developed type-1 gastric carcinoids and underwent regular clinical and endoscopic follow-up (median 77 months, range 6-165) after the initial treatment. Those patients showing recurrent disease were treated with somatostatin analogues until carcinoid disappearance. Results: 12/25 patients (33% males, median age 65 years) showed recurrent gastric carcinoids and were treated with somatostatin analogues for a median duration of 12 months. Median gastrin and chromogranin A levels, which were 802. pg/mL and 33. U/L, respectively, decreased to 299. pg/mL (. p=. 0.002) and 15.6. U/L (. p=. 0.001) at the end of the treatment. Gastric carcinoids disappeared after a median length of treatment of 12 months. After a median time of 19.5 months from somatostatin analogues discontinuation, 4/12 patients (25% males, median age 56 years) showed a further recurrence. A new cycle of treatment was performed successfully. Conclusions: This study confirms that type-1 gastric carcinoids are a recurring disease and somatostatin analogues, administered on 12-month cycles, represent an effective treatment.
Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis / S. Massironi, A. Zilli, I. Fanetti, C. Ciafardini, D. Conte, M. Peracchi. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 47:11(2015), pp. 978-983.
|Titolo:||Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis|
MASSIRONI, SARA (Corresponding)
ZILLI, ALESSANDRA (Secondo)
CONTE, DARIO (Penultimo)
PERACCHI, MADDALENA (Ultimo)
|Parole Chiave:||Lanreotide; Neuroendocrine tumours; Octreotide; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Autoimmune Diseases; Carcinoid Tumor; Chromogranin A; Cohort Studies; Female; Gastrins; Gastritis, Atrophic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Octreotide; Peptides, Cyclic; Prospective Studies; Somatostatin; Stomach Neoplasms; Treatment Outcome; Medicine (all); Hepatology; Gastroenterology|
|Settore Scientifico Disciplinare:||Settore MED/12 - Gastroenterologia|
|Data di pubblicazione:||2015|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.dld.2015.07.155|
|Appare nelle tipologie:||01 - Articolo su periodico|